147 related articles for article (PubMed ID: 32264772)
21. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
22. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
Naidu PS; Singh A; Kulkarni SK
Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
[TBL] [Abstract][Full Text] [Related]
23. An animal model to study the molecular basis of tardive dyskinesia.
Bishnoi M; Boparai RK
Methods Mol Biol; 2012; 829():193-201. PubMed ID: 22231815
[TBL] [Abstract][Full Text] [Related]
24. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.
Tamminga CA; Dale JM; Goodman L; Kaneda H; Kaneda N
Psychopharmacology (Berl); 1990; 102(4):474-8. PubMed ID: 1982902
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.
McCullumsmith RE; Stincic TL; Agrawal SM; Meador-Woodruff JH
Eur J Pharmacol; 2003 Sep; 477(2):101-12. PubMed ID: 14519413
[TBL] [Abstract][Full Text] [Related]
26. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Singh A; Naidu PS; Kulkarni SK
Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
[TBL] [Abstract][Full Text] [Related]
27. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
Bordia T; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Mar; 340(3):612-9. PubMed ID: 22144565
[TBL] [Abstract][Full Text] [Related]
28. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Sharma S; Paladino P; Gabriele J; Saeedi H; Henry P; Chang M; Mishra RK; Johnson RL
Peptides; 2003 Feb; 24(2):313-9. PubMed ID: 12668218
[TBL] [Abstract][Full Text] [Related]
29. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
Bishnoi M; Chopra K; Kulkarni SK
Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214
[TBL] [Abstract][Full Text] [Related]
30. Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
Shi J; Tan YL; Wang ZR; An HM; Li J; Wang YC; Lv MH; Yan SX; Wu JQ; Soares JC; Yang FD; Zhang XY
Pharmacol Biochem Behav; 2016 Sep; 148():53-8. PubMed ID: 27264436
[TBL] [Abstract][Full Text] [Related]
31. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
Shoham S; Mazeh H; Javitt DC; Heresco-Levy U
Brain Res; 2004 Apr; 1004(1-2):142-7. PubMed ID: 15033429
[TBL] [Abstract][Full Text] [Related]
32. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?
Turrone P; Remington G; Nobrega JN
Neurosci Biobehav Rev; 2002 May; 26(3):361-80. PubMed ID: 12034136
[TBL] [Abstract][Full Text] [Related]
33. Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies.
Lister J; Nobrega JN; Fletcher PJ; Remington G
Psychopharmacology (Berl); 2014 Jun; 231(11):2237-49. PubMed ID: 24752659
[TBL] [Abstract][Full Text] [Related]
34. Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.
Thaakur S; Himabindhu G
J Neural Transm (Vienna); 2009 Jul; 116(7):807-14. PubMed ID: 19444377
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Neuropsychopharmacology; 2003 Aug; 28(8):1433-9. PubMed ID: 12838271
[TBL] [Abstract][Full Text] [Related]
36. Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice.
Crowley JJ; Adkins DE; Pratt AL; Quackenbush CR; van den Oord EJ; Moy SS; Wilhelmsen KC; Cooper TB; Bogue MA; McLeod HL; Sullivan PF
Pharmacogenomics J; 2012 Apr; 12(2):147-55. PubMed ID: 21079646
[TBL] [Abstract][Full Text] [Related]
37. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
Kaneda H; Shirakawa O; Dale J; Goodman L; Bachus SE; Tamminga CA
Eur J Pharmacol; 1992 Feb; 212(1):43-9. PubMed ID: 1555638
[TBL] [Abstract][Full Text] [Related]
38. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.
Naidu PS; Singh A; Kulkarni SK
Psychopharmacology (Berl); 2003 Jun; 167(4):418-23. PubMed ID: 12669184
[TBL] [Abstract][Full Text] [Related]
39. Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements.
Sasaki T; Kennedy JL; Nobrega JN
Psychopharmacology (Berl); 1996 Nov; 128(1):97-104. PubMed ID: 8944412
[TBL] [Abstract][Full Text] [Related]
40. Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats.
Fachinetto R; Villarinho JG; Wagner C; Pereira RP; Puntel RL; Paixão MW; Braga AL; Calixto JB; Rocha JB; Ferreira J
Psychopharmacology (Berl); 2007 Oct; 194(3):423-32. PubMed ID: 17641876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
